Cholesterol Rx Drugs Reported Topic Of July NDAC Meeting
This article was originally published in The Tan Sheet
Executive Summary
FDA may be moving toward softening its firm stance, announced in a 1997 guidance, against over-the-counter use of cholesterol-lowering drugs.